Description
Anti-CD30 Antibody, Non-Fucosylated (BioBet-036ZP) is a human monoclonal IgG1 antibody against CD30. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Hodgkin lymphoma, systemic anaplastic large cell lymphoma
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD30 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
TNFRSF8
Full Name
TNFRSF8
Alternative Names
TNF Receptor Superfamily Member 8, Lymphocyte Activation Antigen CD30, CD30L Receptor, Ki-1 Antigen, D1S166E, CD30;
Gene ID
943
UniProt ID
P28908
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with TNFRSF8 include Peripheral T-Cell Lymphoma and Reticulosarcoma.
Related Pathways
Its related pathways are TNF Superfamily - Human Ligand-Receptor Interactions and their Associated Functions and Akt Signaling.
Function
Receptor for TNFSF8/CD30L (PubMed:8391931). May play a role in the regulation of cellular growth and transformation of activated lymphoblasts. Regulates gene expression through activation of NF-kappa-B (PubMed:8999898).
Post-translational modifications
Phosphorylated on serine and tyrosine residues.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
BioBet-036ZP
Description
Brentuximab vedotin, also known as Adcetris®, is an antibody-drug combination drug. Brentuximab vedotin was first approved in 2011 for the treatment of relapsed or refractory Hodgkin's lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL). Brentuximab vedotin selectively targets tumor cells that express the CD30 antigen, which is a classic mark of Hodgkin's lymphoma and ALCL, a T-cell non-Hodgkin's lymphoma.
Antibody Indication
B-large cell anaplastic Lymphoma (Kiel Classification) refractory
Refractory Hodgkin Lymphoma
Post-autologous hematopoietic stem cell transplantation Hodgkin lymphoma
B-large cell anaplastic Lymphoma (Kiel Classification) refractory
Refractory Hodgkin Lymphoma
Post-autologous hematopoietic stem cell transplantation Hodgkin lymphoma
